thioridazine has been researched along with rifampin in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Aínsa, JA; Martín, C; Ramón-García, S; Thompson, CJ | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Alam, MZ; Bruhn, DF; Feng, L; Hurdle, JG; Lee, RB; Lee, RE; Maddox, MM; Narula, G; Sandhaus, S; Simmons, CJ; Sun, D; Tse-Dinh, YC; Tsutsumi, LS; Wu, X | 1 |
| Dixit, PP; Thore, SN | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bhakta, S; Brown, AK; Castagnolo, D; Maitra, A; Manetti, F; Pavan, FR; Petricci, E; Ribeiro, CM; Scalacci, N; Smith, DL | 1 |
| Aziz, DB; Dick, T; Go, ML; Gopal, P; Li, M; Nyantakyi, SA | 1 |
| Barreca, ML; Bojarski, AJ; Cecchetti, V; Cook, GM; Desantis, J; Felicetti, T; Franzblau, SG; Handzlik, J; Hards, K; Kolář, MH; Latacz, G; Manfroni, G; Massari, S; Mazzarella, MA; Nakatani, Y; Nizi, MG; Rushton-Green, R; Sabatini, S; Satała, G; Shetye, G; Tabarrini, O | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Amaral, L; Viveiros, M | 1 |
| Amaral, L; Baptista, P; Couto, I; Machado, D; Perdigão, J; Portugal, I; Rodrigues, L; Veigas, B; Viveiros, M | 1 |
| Gumbo, T; Leff, R; Meek, C; Musuka, S; Pasipanodya, J; Siyambalapitiyage Dona, CW; Srivastava, S | 1 |
| Dutta, NK; Karakousis, PC; Pinn, ML | 2 |
| Dutta, NK; Karakousis, PC | 1 |
| Sharma, S; Singh, A | 1 |
| Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D | 1 |
| Anes, E; Bogoeva, V; Fenaroli, F; Griffiths, G; Hildahl, J; Kalluru, R; Pires, D; Speth, M; Vibe, CB; Wilson, SR | 1 |
| Britton, WJ; Chan, HK; Chan, JG; Pang, A; Parumasivam, T; Quan, DH; Triccas, JA | 1 |
2 review(s) available for thioridazine and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
25 other study(ies) available for thioridazine and rifampin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
Topics: Antitubercular Agents; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Clofazimine; Dithiothreitol; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Glutathione; Hydrogen Peroxide; Membrane Transport Proteins; Mutation; Mycobacterium tuberculosis; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Rifampin; Valinomycin | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.
Topics: Animals; Anti-Bacterial Agents; Chalcones; Chemistry Techniques, Synthetic; Chlorocebus aethiops; Chromones; DNA Gyrase; DNA Topoisomerase IV; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phloroglucinol; Structure-Activity Relationship; Topoisomerase II Inhibitors; Vero Cells | 2014 |
Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
Topics: Antitubercular Agents; Cells, Cultured; Chemistry Techniques, Synthetic; Drug Design; Drug Evaluation, Preclinical; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium tuberculosis; Triazoles | 2016 |
Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
Topics: Antitubercular Agents; Cell Line; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Multiple; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; Thioridazine | 2017 |
Indolylalkyltriphenylphosphonium Analogues Are Membrane-Depolarizing Mycobactericidal Agents.
Topics: | 2017 |
Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Synergism; Enzyme Inhibitors; HEK293 Cells; Humans; Microsomes, Liver; Molecular Structure; Mycobacterium smegmatis; Mycobacterium tuberculosis; NADH Dehydrogenase; Organoselenium Compounds; Parasitic Sensitivity Tests; Phenothiazines; Protein Binding; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Vero Cells | 2020 |
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.
Topics: Antibiotics, Antitubercular; Chlorpromazine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Synergism; Humans; Immunologic Factors; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenothiazines; Promethazine; Rifampin; Streptomycin; Thioridazine | 2001 |
Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Biological Transport, Active; Carrier Proteins; Catalase; Chlorpromazine; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Gene Expression; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Rifampin; Thioridazine; Tuberculosis, Multidrug-Resistant; Verapamil | 2012 |
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
Topics: Antipsychotic Agents; Antitubercular Agents; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Design; Drug Repositioning; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Isoniazid; Latent Tuberculosis; Microbial Sensitivity Tests; Models, Statistical; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Thioridazine; Time Factors | 2013 |
Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.
Topics: Animals; Antipsychotic Agents; Antitubercular Agents; Disease Models, Animal; Drug Repositioning; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Thioridazine; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Thioridazine; Tuberculosis, Pulmonary | 2014 |
Thioridazine for treatment of tuberculosis: promises and pitfalls.
Topics: Animals; Antitubercular Agents; Female; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Thioridazine; Tuberculosis | 2014 |
Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Isoniazid; Latent Tuberculosis; Male; Mice; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Rifampin; Thioridazine | 2014 |
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Isoniazid; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Stem Cells; Thioridazine; Tuberculosis | 2014 |
Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.
Topics: Animals; Antitubercular Agents; Cell Survival; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Lactic Acid; Macrophages; Male; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rifampin; Thioridazine; Tuberculosis; Zebrafish | 2016 |
In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Topics: Administration, Inhalation; Antitubercular Agents; Humans; In Vitro Techniques; Powder Diffraction; Powders; Rifampin; Thioridazine; Tuberculosis | 2016 |